Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PPIA | P62937 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840434 | 0.91 | MAPT (0.70) | PKMALDH1A1MAPTLMNAPPIA | |
| SCHEMBL15840701 | 0.88 | MAPT (0.66) | ALDH1A1MAPTLMNAPPIAMEN1 | |
| SCHEMBL15840810 | 0.86 | LMNA (0.74) | ALDH1A1MAPTLMNAPPIAMEN1 | |
| SCHEMBL15840811 | 0.85 | MAPT (0.70) | ALDH1A1MAPTLMNAPPIAMEN1 | |
| SCHEMBL15840508 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPTLMNAPPIAMEN1 | |
| SCHEMBL13453919 | 0.84 | PKM (0.58) | PKMALDH1A1MAPTLMNAPPIA | |
| SCHEMBL15840679 | 0.84 | PPIA (0.57) | PKMALDH1A1MAPTLMNAPPIA | |
| SCHEMBL15840655 | 0.82 | ALDH1A1 (0.71) | PKMALDH1A1MAPTLMNAPPIA | |
| SCHEMBL15840707 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MAPTLMNAPPIAKMT2A | |
| SCHEMBL15840660 | 0.82 | PPIA (0.62) | PKMALDH1A1MAPTLMNAPPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | PKM 4157/4885ALDH1A1 4348/4885MAPT 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.